TABLE 1.
Patient and healthcare workers demographics, isolation sites, clonal characteristics, and antibiotic susceptibilities of MRSA isolate
| Isolate identifier | Age | Sex | Diagnosis | Isolation site | Therapy | Outcome | PFGE | spa type | SCCmec type | Cefoxitin | Ciprofloxacin | Clindamycin | Daptomycin | Erythromycin | Fusidic acid | Gentamicin | Levofloxacin | Linezolid | Rifampicin | Tetracycline | TMP-SXT | Tobramycin | Vancomycin |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Patients’ isolates | |||||||||||||||||||||||
| CI-1 | 48 | M | Pneumonia | Blood | PIP-TZP 4.5 g IV TID; Daptomycin 500 mg IV daily | Died | A | t030 | Type III | R | R | R | S | R | S | R | R | S | R | R | S | R | S |
| CI-2 | 79 | F | Cerebrovascular disease | Trachea | Linezolid 600 mg IV BID | Discharged | A | t030 | Type III | R | R | R | S | R | S | R | R | S | R | R | S | R | S |
| CI-3 | 74 | F | Meninx benign neoplasm | Trachea | Vancomycin 1 g IV daily | Died | A | t030 | Type III | R | R | R | S | R | S | R | R | S | R | R | S | R | S |
| CI-4 | 68 | M | Colon cancer | Blood | Daptomycin 350 mg IV daily | Discharged | A | t030 | Type III | R | R | R | S | R | S | R | R | S | R | R | S | R | S |
| CI-5 | 46 | F | Falling from high | Trachea | Tigecycline 50 mg IV BID; Meropenem 1 g IV TID | Discharged | A | t030 | Type III | R | R | R | S | R | S | R | R | S | R | R | S | R | S |
| CI-6 | 49 | F | Over cancer | Blood | Vancomycin 1 g IV BID | Discharged | A | t030 | Type III | R | R | R | S | R | S | R | R | S | R | R | S | R | S |
| CI-7 | 88 | M | Colon cancer | Abscess | Tigecycline 50 mg IV BID; Meropenem 1 g IV TID | Discharged | A | t030 | Type III | R | R | R | S | R | S | R | R | S | R | R | S | R | S |
| CI-8 | 23 | M | Drug user, intoxication | Blood | Tigecycline 50 mg IV BID; Meropenem 1 g IV TID | Discharged | A | t030 | Type I | R | R | S | S | S | S | S | R | S | R | R | S | S | S |
| CI-9 | 86 | M | Fournier’s gangrene | Blood | Linezolid 600 mg BID | Died | A | t030 | Type III | R | R | S | S | S | S | S | R | S | R | R | S | S | S |
| Screening cultures isolates | |||||||||||||||||||||||
| Pt-S-1 | 63 | K | Cerebellar tumor, epilepsy | Throat, nasal | Vancomycin 1 g IV BID | Died | C | t459 | Type III | R | R | R | S | R | S | R | R | S | R | R | S | R | S |
| Pt-S-2* | 74 | F | Meninx benign neoplasm | Nasal, groin | Vancomycin 1 g IV daily | Died | A | t030 | Type III | R | R | R | S | R | S | R | R | S | R | R | S | R | S |
| Pt-S-3** | 86 | M | Fournier’s gangrene | Throat, nasal, groin, rectum | Linezolid 600 mg IV BID | Died | A | t030 | Type III | R | R | R | S | R | S | R | R | S | R | R | S | R | S |
| HCW-1 | 44 | E | Nasal | TMP-SXT 160/800 mg PO BID | A | t030 | Type III | R | R | R | S | R | S | R | R | S | R | R | S | R | S | ||
| HCW-2 | 23 | E | Nasal | TMP-SXT 160/800 mg PO BID | D | ND | Type III | R | R | R | S | R | S | R | R | S | R | R | S | R | S | ||
| HCW-3 | 28 | E | Nasal | TMP-SXT 160/800 mg PO BID | A | t030 | Type V | R | R | R | S | R | S | R | R | S | R | R | S | R | S | ||
| HCW-4 | 30 | K | Nasal | Not decolonized | A | t030 | Type III | R | R | S | S | S | S | S | R | S | R | R | S | S | S | ||
| HCW-5 | 24 | K | Nasal | TMP-SXT 160/800 mg PO BID | B | t030 | Type I | R | R | S | S | S | S | S | R | S | R | R | S | S | S |
BID: 2 times a day, CI: clinical isolate, F: female, HCW: healthcare worker, IV: intravenous, M: male, MRSA: methicillin-resistant Staphylococcus aureus, PIP-TZP: piperacillin/tazobactam, PO: by mouth, Pt-S: patient screening, R: resistant, S: susceptible, TID: 3 times a day, TMP-SXT: trimethoprim/sulfamethoxazole
*
Pt-S-2 and CI-3 belonged to the same patient;
**
Pt-S-3 and CI-9 belonged to the same patient